The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fontana, A.
Right arrow Articles by Weber, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fontana, A.
Right arrow Articles by Weber, E.

The Journal of Immunology, Vol 132, Issue 4 1837-1844, Copyright © 1984 by American Association of Immunologists

ARTICLES

Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects

A Fontana, H Hengartner, N de Tribolet and E Weber

Studies were designed to investigate whether the cellular immunodeficiency state observed in human glioblastoma patients could be due to inhibitory factors released by the tumor cells. Cultured human glioblastoma cells were found to secrete an interleukin 1-like factor (m.w. 22,000) and a factor (m.w. 97,000) that inhibits interleukin 2 (IL 2)-dependent T cell mechanisms. This is demonstrated by its inhibitory effect on the IL 2-induced proliferation of T cell clones and on the induction of alloreactive cytotoxic T cells in mixed lymphocyte cultures. Additionally the glioblastoma cell-derived 97,000- m.w. factor inhibited growth of neuroblasts but not of fibroblasts and thus shares the characteristics of the neuroblast growth inhibition factor (NGIF) previously detected in the supernatant of fetal rat glia cell cultures. If released by glioblastoma cells in vivo, the factor may contribute to impaired immunosurveillance and to the cellular immunodeficiency state detected in the patients.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
P. Roth, S. Aulwurm, I. Gekel, D. Beier, R. G. Sperry, M. Mittelbronn, R. Meyermann, K. D. Beaman, M. Weller, and J. Wischhusen
Regeneration and tolerance factor: a novel mediator of glioblastoma-associated immunosuppression.
Cancer Res., April 1, 2006; 66(7): 3852 - 3858.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Uhl, S. Aulwurm, J. Wischhusen, M. Weiler, J. Y. Ma, R. Almirez, R. Mangadu, Y.-W. Liu, M. Platten, U. Herrlinger, et al.
SD-208, a Novel Transforming Growth Factor {beta} Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo
Cancer Res., November 1, 2004; 64(21): 7954 - 7961.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. A. Friese, J. Wischhusen, W. Wick, M. Weiler, G. Eisele, A. Steinle, and M. Weller
RNA Interference Targeting Transforming Growth Factor-{beta} Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity In vivo
Cancer Res., October 15, 2004; 64(20): 7596 - 7603.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. W. Landen, V. Hau, M. Wang, T. Davis, B. Ciliax, B. H. Wainer, E. G. Van Meir, J. D. Glass, H. C. Joshi, and D. R. Archer
Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth
Clin. Cancer Res., August 1, 2004; 10(15): 5187 - 5201.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. Maggard, L. Meng, B. Ke, R. Allen, L. Devgan, BS, and D. K. Imagawa
Antisense TGF-{beta}2 Immunotherapy for Hepatocellular Carcinoma: Treatment in a Rat Tumor Model
Ann. Surg. Oncol., January 1, 2001; 8(1): 32 - 37.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
M. Galdiero, M. D'Amico, F. Gorga, C. Di Filippo, M. D'Isanto, M. Vitiello, A. Longanella, and A. Tortora
Haemophilus influenzae Porin Contributes to Signaling of the Inflammatory Cascade in Rat Brain
Infect. Immun., January 1, 2001; 69(1): 221 - 227.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. Sampath, J. Hanes, F. DiMeco, B. M. Tyler, D. Brat, D. M. Pardoll, and H. Brem
Paracrine Immunotherapy with Interleukin-2 and Local Chemotherapy Is Synergistic in the Treatment of Experimental Brain Tumors
Cancer Res., May 1, 1999; 59(9): 2107 - 2114.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Pardoux, X. Ma, S. Gobert, S. Pellegrini, P. Mayeux, F. Gay, G. Trinchieri, and S. Chouaib
Downregulation of Interleukin-12 (IL-12) Responsiveness in Human T Cells by Transforming Growth Factor-beta : Relationship With IL-12 Signaling
Blood, March 1, 1999; 93(5): 1448 - 1455.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
J. H. Sampson
THE PREUSS FOUNDATION SEMINAR ON VACCINE THERAPY FOR MALIGNANT PRIMARY BRAIN TUMORS February 15-17, 199 8, La Jolla, Calif.
Neuro-oncol, January 1, 1999; 1(1): 33 - 42.
[PDF]

Home page
 J. Neurosci.Home page
A. de Luca, M. Weller, and A. Fontana
TGF-beta -Induced Apoptosis of Cerebellar Granule Neurons Is Prevented by Depolarization
J. Neurosci., July 1, 1996; 16(13): 4174 - 4185.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1984 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1984 by The American Association of Immunologists, Inc. All rights reserved.